- Home
- FCF vs PRAX Comparison
FCF vs PRAX Comparison
Compare FCF & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCF
- PRAX
- Stock Information
- Founded
- FCF 1934
- PRAX 2015
- Country
- FCF United States
- PRAX United States
- Employees
- FCF N/A
- PRAX N/A
- Industry
- FCF Major Banks
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- FCF Finance
- PRAX Health Care
- Exchange
- FCF Nasdaq
- PRAX Nasdaq
- Market Cap
- FCF 1.7B
- PRAX 730.1M
- IPO Year
- FCF N/A
- PRAX 2020
- Fundamental
- Price
- FCF $15.47
- PRAX $37.29
- Analyst Decision
- FCF Buy
- PRAX Strong Buy
- Analyst Count
- FCF 7
- PRAX 10
- Target Price
- FCF $19.36
- PRAX $123.80
- AVG Volume (30 Days)
- FCF 581.7K
- PRAX 669.5K
- Earning Date
- FCF 04-22-2025
- PRAX 02-28-2025
- Dividend Yield
- FCF 3.33%
- PRAX N/A
- EPS Growth
- FCF N/A
- PRAX N/A
- EPS
- FCF 1.39
- PRAX N/A
- Revenue
- FCF $448,502,000.00
- PRAX $8,553,000.00
- Revenue This Year
- FCF $11.90
- PRAX N/A
- Revenue Next Year
- FCF $9.80
- PRAX $2,780.59
- P/E Ratio
- FCF $11.23
- PRAX N/A
- Revenue Growth
- FCF N/A
- PRAX 249.53
- 52 Week Low
- FCF $12.41
- PRAX $30.01
- 52 Week High
- FCF $19.96
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- FCF 34.90
- PRAX 27.33
- Support Level
- FCF $15.23
- PRAX $34.91
- Resistance Level
- FCF $16.58
- PRAX $39.44
- Average True Range (ATR)
- FCF 0.36
- PRAX 4.03
- MACD
- FCF -0.06
- PRAX -1.56
- Stochastic Oscillator
- FCF 17.52
- PRAX 16.46
About FCF First Commonwealth Financial Corporation
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.